Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m [Yahoo! Finance]
Eliem Therapeutics, Inc (ELYM)
Company Research
Source: Yahoo! Finance
Significant control over Eliem Therapeutics by private equity firms implies that the general public has more power to influence management and governance-related decisions A total of 2 investors have a majority stake in the company with 54% ownership A look at the shareholders of Eliem Therapeutics, Inc. ( NASDAQ:ELYM ) can tell us which group is most powerful. With 53% stake, private equity firms possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). While institutions, who own 27% shares weren't spared from last week's US$231m market cap drop, private equity firms as a group suffered the maximum losses Let's delve deeper into each type of owner of Eliem Therapeutics, beginning with the chart below. What Does The Institutional Ownership Tell Us About Eliem Therapeutics? Many institutions measure their performance against an index that approximates the local market. So they usu
Show less
Read more
Impact Snapshot
Event Time:
ELYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELYM alerts
High impacting Eliem Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
ELYM
News
- Eliem Therapeutics rebrands as Climb Bio with new name and logo [Seeking Alpha]Seeking Alpha
- Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.GlobeNewswire
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitGlobeNewswire
- Eliem Therapeutics Announces Additions to its Leadership TeamGlobeNewswire
ELYM
Sec Filings
- 10/2/24 - Form 8-K
- 9/20/24 - Form 4
- 8/27/24 - Form 8-K
- ELYM's page on the SEC website